Well, the source is the paper that he is highlighting.
Not really. The premise of Derek Lowe’s blog is that GSK was conned by some fast talking Harvard guys at Sirtis and ended up paying big money for nothing. This strikes me as a stretch.
Its hard to believe that GSK did not send over a team to do DD. I have always thought they bought Sirtruis because the company has patented most of the possible sirtrim activators. Its gonna be very interesting to see how it plays out.
Market Data 
Markets 
AI
